AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The tumor-associated antigen STEAP1 is a potential therapeutic target that is expressed in most prostate tumors and at increased levels in metastatic castration-resistant prostate cancer (mCRPC). We developed a STEAP1-targeted XmAb 2+1 T-cell engager (TCE) molecule, AMG 509 (also designated xaluritamig), that is designed to redirect T cells to kill prostate cancer cells that express STEAP1. AMG 509 mediates potent T cell–dependent cytotoxicity of prostate cancer cell lines in vitro and promotes tumor regression in xenograft and syngeneic mouse models of prostate cancer in vivo. The avidity-driven activity of AMG 509 enables selectivity for tumor cells with high STEAP1 expression compared with normal cells. AMG 509 is the first STEAP1 TCE to advance to clinical testing, and we report a case study of a patient with mCRPC who achieved an objective response on AMG 509 treatment. Significance: Immunotherapy in prostate cancer has met with limited success due to the immunosuppressive microenvironment and lack of tumor-specific targets. AMG 509 provides a targeted immunotherapy approach to engage a patient's T cells to kill STEAP1-expressing tumor cells and represents a new treatment option for mCRPC and potentially more broadly for prostate cancer. See related commentary by Hage Chehade et al., p. 20. See related article by Kelly et al., p. 76. This article is featured in Selected Articles from This Issue, p. 5
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Jiao, S., Subudhi, S. K., Aparicio, A., Ge, Z., Guan, B., Miura, Y., & Sharma, P. (2019) · Cell · doi:10.1016/j.cell.2019.10.029 · Cited by 386
Fallah, J., Agrawal, S., Gittleman, H., Fiero, M. H., Subramaniam, S., John, C., Chen, W., Ricks, T. K., Niu, G., Fotenos, A., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2875 · Cited by 255
Hummel, H.-D., Kufer, P., Grüllich, C., Seggewiss-Bernhardt, R., Deschler-Baier, B., Chatterjee, M., Goebeler, M.-E., Miller, K., de Santis, M., Loidl, W., et al. (2021) · Immunotherapy · doi:10.2217/imt-2020-0256 · Cited by 154
Zuch de Zafra, C. L., Fajardo, F., Zhong, W., Bernett, M. J., Muchhal, U. S., Moore, G. L., Stevens, J., Case, R., Pearson, J. T., Liu, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2752 · Cited by 132
Self-citationKelly, W. K., Danila, D. C., Lin, C.-C., Lee, J.-L., Matsubara, N., Ward, P. J., Armstrong, A. J., Pook, D., Kim, M., Dorff, T. B., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0964 · Cited by 125
Self-citationXu, M., Evans, L., Bizzaro, C. L., Quaglia, F., Verrillo, C. E., Li, L., Stieglmaier, J., Schiewer, M. J., Languino, L. R., & Kelly, W. K. (2022) · Cancers · doi:10.3390/cancers14164034 · Cited by 61
Self-citationGomes, I. M., Rocha, S. M., Gaspar, C., Alvelos, M. I., Santos, C. R., Socorro, S., & Maia, C. J. (2018) · Medical Oncology · doi:10.1007/s12032-018-1100-0 · Cited by 51
Cited by
The present and future of bispecific antibodies for cancer therapy
Klein, C., Brinkmann, U., Reichert, J. M., & Kontermann, R. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00896-6 · Cited by 490
Kelly, W. K., Danila, D. C., Lin, C.-C., Lee, J.-L., Matsubara, N., Ward, P. J., Armstrong, A. J., Pook, D., Kim, M., Dorff, T. B., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0964 · Cited by 125
Self-citationDorff, T., Horvath, L. G., Autio, K., Bernard-Tessier, A., Rettig, M. B., Machiels, J.-P., Bilen, M. A., Lolkema, M. P., Adra, N., Rottey, S., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2978 · Cited by 76
Lampe, H., Tam, L., & Hansen, A. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399802 · Cited by 21
Metadata
- Authors
- Nolan-Stevaux, O., Li, C., Liang, L., Zhan, J., Estrada, J., Osgood, T., Li, F., Zhang, H., Case, R., Murawsky, C. M., Estes, B., Moore, G. L., Bernett, M. J., Muchhal, U., Desjarlais, J. R., Staley, B. K., Stevens, J., Cooke, K. S., Aeffner, F., Thomas, O., Stieglmaier, J., Lee, J.-L., Coxon, A., & Bailis, J. M.
- Venue
- Cancer Discovery
- Published
- 2023-10-20
- Volume
- 14
- Issue
- 1
- Pages
- 90-103
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W4387797966
- Cited by
- 55
- References
- 8
- FWCI
- 8.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-23-0984
- The paper
- Nolan-Stevaux, O., Li, C., Liang, L., Zhan, J., Estrada, J., Osgood, T., Li, F., Zhang, H., Case, R., Murawsky, C. M., Estes, B., Moore, G. L., Bernett, M. J., Muchhal, U., Desjarlais, J. R., Staley, B. K., Stevens, J., Cooke, K. S., Aeffner, F., . . . Bailis, J. M. (2024). AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-23-0984
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.